Alpha-GPC

Alpha-GPC does real things, but there is a safety signal you need to weigh before you make it a daily habit. Alpha-GPC is a choline precursor (a compound your body converts into the brain chemical acetylcholine), and it has solid acute benefits for power output in athletes and for cognition in older adults with decline. The hard part is a 2021 study. A 10-year cohort of 12 million South Korean adults (Lee et al., PMID 34817582) found that people who used Alpha-GPC had 46% higher stroke risk, with the risk climbing the more they took (a dose-response relationship), and the likely culprit is a gut-derived compound called TMAO. The upside is real too: 600mg before a workout increases power output, and 1,200mg daily improved cognition and even reversed shrinkage in part of the brain (temporal lobe atrophy) in mild-to-moderate Alzheimer's. Our read: if you have cardiovascular risk factors, skip it. If you don't, cycle it rather than taking it every day forever.

If you're using it for the gym, the question is mostly about timing and dose. Research shows 600mg taken 60-90 minutes before exercise increases power output compared to a placebo. Bellar et al. (2015, n=48) found a statistically significant 98.8 Newton bump in isometric mid-thigh pull peak force after 6 days at 600mg. Ziegenfuss et al. (2008) found a 14% improvement in peak bench press power and a 44-fold spike in growth hormone versus 2.6-fold on placebo. One wrinkle worth knowing before you reach for the biggest dose: a separate study (Perez-Pinero et al., PMC5629791) found 250mg improved maximum velocity and mechanical power during a countermovement jump more than 500mg, caffeine 200mg, or placebo did - hinting that more isn't always better and that over-saturating may backfire. The performance research points the right way, but the studies are still moderate in size.

If you're a healthy adult hoping for a focus or memory edge, this is the newest and weakest part of the picture, so keep expectations modest. The signal has firmed up lately. Marcus et al. 2024 (n=20, DB crossover) showed both 630mg and 315mg improved executive function (Stroop performance) versus placebo. Tamura et al. 2021 found 400mg increased self-reported motivation without changing mood. Almost all of this came from 2020-2024 research, so it's early.

Where the evidence is strongest is in older adults already experiencing cognitive decline. A large multicenter trial found that 1,200mg/day over 180 days produced significant cognitive improvements in patients with mild to moderate Alzheimer's dementia. A later brain-imaging (MRI) trial found that 1,200mg/day for 36 months alongside the drug donepezil 10mg reversed shrinkage in the temporal lobe, hippocampus, and amygdala - while donepezil on its own showed no such structural change. A 2025 meta-analysis (Sagaro et al., PMID: 41426989) found Alpha-GPC beat citicoline (another choline source) on overall clinical status (SCAG WMD: -3.92), though the two were neck-and-neck on direct memory recall.

Now the part that should shape your decision. The biggest safety concern is that same 10-year cohort study (Lee et al. 2021, n=12 million, South Korea NHIS database): Alpha-GPC users had a 46% higher risk of stroke than non-users (adjusted HR 1.46, 95% CI 1.43-1.48). That higher risk showed up for both kinds of stroke - ischemic (aHR 1.36) and hemorrhagic (aHR 1.36) - and it followed a dose-response pattern, meaning the more people took over time, the higher their risk. The mechanism runs through your gut: certain gut bacteria (those carrying the cutC gene) turn choline into trimethylamine (TMA), and the liver enzyme FMO3 then converts that into TMAO - a compound that fuels inflammation, accelerates artery hardening (atherosclerosis), and makes platelets stickier. The link held up after the researchers matched users to similar non-users (aHR 1.43) and even after they tossed out strokes in the first 4 years to rule out the disease quietly driving the stroke (reverse causality). Animal data backs the mechanism: mice bred to be prone to atherosclerosis (ApoE-/-) that were fed Alpha-GPC shifted their gut bacteria toward TMA-producers and developed worse arterial plaque. Two honest caveats: this is observational data, not a randomized trial, and the people in it were older adults already managing health conditions on prescription Alpha-GPC. Even so, the sheer size, the consistency, and the fact that the biology makes sense mean we treat this as a serious reason for caution with chronic high-dose use.